ascopubs.org

Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.

Should women take part in clinical trials in breast cancer? Issues and some solutions. ICAM-1 expression was negative (-) in 14 patients (20%), weak (+) in 21 (30%), positive (++) in 30 (43%), and ...
ascopubs.org

Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly ...

Clinical and genomic characterisation of adenoid cystic carcinoma of the head and neck, lung, and breast. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...
BioWorld

ICAM-1 orchestrates radiotherapy abscopal effect

A study led by Chinese radiologists at Peking University in Beijing has shown that positron emission tomography (PET) imaging of intercellular adhesion molecule-1 (ICAM-1) expression is a predictor ...
EurekAlert!

ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy

Radiotherapy (RT) is one of the most widely used cancer treatment modalities, applied in over half of all patients with cancer. In clinical oncology, positron emission tomography (PET) with 18 ...
BioWorld

Innovstone patents new LFA-1/ICAM-1 interaction inhibitors

Innovstone Therapeutics Ltd. has disclosed integrin αLβ2 (LFA-1)/ICAM-1 interaction inhibitors and/or RASP-trapping agents reported to be useful for the treatment of dry eye syndrome.